Key result
Alcoholic liver disease and MASLD linked to systemic vascular dysfunction and PAD progression.
Why the study?
Emerging evidence suggests alcohol consumption, alcoholic liver disease, and metabolic-associated steatotic liver disease may contribute to PAD risk beyond traditional cardiovascular risk factors.
Do alcohol consumption and liver disease contribute to peripheral arterial disease risk?
Do alcohol consumption and liver disease contribute to peripheral arterial disease risk?
This review highlights the emerging role of alcoholic and metabolic-associated steatotic liver diseases in systemic vascular dysfunction and PAD progression, suggesting a potential need for PAD screening in these high-risk patients.
Answers are grounded in this paper and cite their sources.
May prompt PAD risk assessment in liver disease patients; leaves open prospective validation of causality and screening.
Peripheral arterial disease (PAD) is a major vascular complication associated with significant morbidity and mortality. While traditional cardiovascular risk factors such as smoking, hypertension, and diabetes are well established, emerging evidence suggests that alcohol consumption, alcoholic liver disease, and metabolic-associated steatotic liver disease may also contribute to PAD risk. This review synthesizes current epidemiological evidence linking alcohol intake, alcoholic liver disease, and metabolic-associated steatotic liver disease to PAD and explores potential mechanisms, including atherosclerosis, endothelial dysfunction, chronic inflammation, dyslipidemia, and coagulation abnormalities. Observational studies suggest a possible protective effect of light-to-moderate alcohol consumption though genetic studies challenge this notion. In addition, alcoholic liver disease and metabolic-associated steatotic liver disease are increasingly recognized as contributors to systemic vascular dysfunction and PAD progression. In conclusion, given the rising burden of liver disease, it is crucial to determine whether PAD screening is warranted in patients with high-risk alcoholic liver disease and metabolic-associated steatotic liver disease. Addressing modifiable risk factors and optimizing pharmacological interventions may help mitigate PAD risk. Future research should focus on longitudinal studies, sex- and ethnicity-specific differences, and omics-based approaches to refine risk prediction, early detection, and targeted interventions.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2025) conducted a review in Peripheral arterial disease and liver disease. Alcohol consumption and liver disease was evaluated. Alcoholic liver disease and metabolic-associated steatotic liver disease are increasingly recognized as contributors to systemic vascular dysfunction and peripheral arterial disease progression.
Synapse has enriched 10 related papers. Consider them for comparative context: